ALLOGENE THERAP (ALLO)

ALLO stock results show that Allogene Therapeutics missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.

Allogene Layoffs 2024: What to Know About the Latest ALLO Job Cuts

By Chris MacDonald, InvestorPlace Contributor Jan 5, 2024

Today, investors in Allogene and ALLO stock aren't cheering a cash burn reduction strategy, with the stock sinking over 15% on the news.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

By William White, InvestorPlace Writer Jan 5, 2024

Pre-market stock movers are worth checking on Friday as we lay out all of the biggest stories worth keeping tabs on this morning!

7 Penny Stocks With Low Floats and High Short Interest

By Thomas Niel, InvestorPlace Contributor Nov 24, 2023

Is the 'smart money' on the money shorting these low-float penny stocks, or is there the opportunity for a short squeeze? Let's find out.

Short Squeeze Alert: The 5 Most Shorted Stocks Right Now

By Samuel O'Brient, InvestorPlace Reporter Jun 22, 2023

Wondering what are the most shorted stocks this year? Here are the top five companies investors are betting against.

7 Short-Interest Stocks to Target for Explosive Gains

By Josh Enomoto, InvestorPlace Contributor May 18, 2023

For contrarian investors that can stand the heat, short-interest stocks to buy can offer significant rewards in a short time period.

7 Short-Squeeze Stocks That Could Make You Rich

By Josh Enomoto, InvestorPlace Contributor Apr 13, 2023

Although moving against the grain presents its own distinct set of risks, these short-squeeze stocks may profit the contrarian.

7 Short-Squeeze Stocks That Could Explode in April

By Josh Enomoto, InvestorPlace Contributor Mar 30, 2023

Although these short-squeeze stocks attracted bearish attention justifiably, contrarian sentiment may see them jump higher.

ALLOGENE THERAP (ALLO)

7 Biotech Stocks to Buy for Their Game-Changing Potential

If You Can Only Buy One Penny Stock in May, It Better Be One of These 3 Names

ALLO Stock Earnings: Allogene Therapeutics Beats EPS, Beats Revenue for Q1 2024

3 Meme Stocks to Sell and Replace With Meme Coins

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

ALLOGENE THERAP (ALLO)

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

ALLO Stock Predictions, Articles, and ALLOGENE THERAP News

Subscriber Sign in